Idiopathic Inflammatory Myopathies (IIMs) — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Idiopathic inflammatory myopathies (IIMs) represent a cluster of autoimmune disorders marked by muscle inflammation (myositis) and involvement of other organs, leading to broad organ dysfunction, heightened morbidity, and premature mortality. Presently, IIMs are categorized into distinct subtypes:
- Dermatomyositis (DM) includes classic dermatomyositis, juvenile dermatomyositis, and clinical amyopathic dermatomyositis. These may be linked with connective tissue disorders (CTDs) and malignancies.
- Polymyositis (PM), comprising classical PM and nonspecific or overlap myositis, is often associated with CTDs.
- Autoimmune necrotizing myopathy, connected with malignancies, statin use, and CTDs.
- Sporadic IBM is occasionally associated with CTDs.
These conditions arise due to prolonged immune activity triggered by exposure to environmental risk factors in individuals with a genetic predisposition. Diagnosing IIM can be straightforward when patients display typical muscle weakness, evident multisystem involvement, and a consistent serological profile. However, in clinical settings, many patients present with nonspecific symptoms such as fever, fatigue, myalgia, and arthralgia. Typically, IIM manifests acute or subacute symmetrical muscle weakness in proximal and leg muscles. This weakness may manifest as difficulty in simple tasks like combing hair or rising from a chair, and in severe cases, it may affect functions like speech or swallowing. Corticosteroids are the cornerstone of treatment for polymyositis and dermatomyositis (PM/DM), with prednisone usually starting at 1 to 2 mg/kg/day. In severe cases, intravenous methylprednisolone at 1 mg/kg/day for three consecutive days may be administered. Steroid-sparing therapies like methotrexate and azathioprine are options for those experiencing adverse effects or difficulties tapering off steroids, especially in individuals with normal thiopurine methyltransferase (TPMT) activity.
- The estimated prevalence of IIM ranges from 14.0 to 21.4 cases per 100,000 population in the United States.
Thelansis’s “Idiopathic Inflammatory Myopathies (IIMs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Idiopathic Inflammatory Myopathies (IIMs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Idiopathic Inflammatory Myopathies (IIMs) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Idiopathic Inflammatory Myopathies (IIMs) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
